Niki Momin, FNP | |
10710 N Torrey Pines Rd, La Jolla, CA 92037-1035 | |
(979) 571-5201 | |
Not Available |
Full Name | Niki Momin |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 10710 N Torrey Pines Rd, La Jolla, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427724962 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 1048213 (Texas) | Secondary |
363L00000X | Nurse Practitioner | 95018385 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Niki Momin, FNP 10710 N Torrey Pines Rd, La Jolla, CA 92037-1035 Ph: (979) 571-5201 | Niki Momin, FNP 10710 N Torrey Pines Rd, La Jolla, CA 92037-1035 Ph: (979) 571-5201 |
News Archive
NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring of individual patients, and the assessment of drug diversion of a new pain management drug therapy.
Although school has just begun, it is already exam time for students throughout Wisconsin. That's because in addition to notebook paper and pens, back-to-school preparations should also include routine health exams to make sure students are healthy and ready to learn. These include: a doctor's exam to confirm that all immunizations are up-to-date, a dental exam and a vision exam.
Patients with heart disease who undergo coronary angioplasty have an equivalent risk of death and heart attack as patients who undergo coronary bypass surgery, according to Stanford University School of Medicine researchers.
Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.
The incidence of Alzheimer's disease (AD) is expected to triple in the coming decades and no cure has been found. Recently, interest in dietary approaches for prevention of cognitive decline has increased.
› Verified 3 days ago